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Abstract
It is generally thought that mucosal fluids protect underlying epithelial surfaces against
opportunistic infection via their antimicrobial activity. However, our published data show that
human tear fluid can protect against the major opportunistic pathogen Pseudomonas aeru-
ginosa independently of bacteriostatic activity. Here, we explored the mechanisms for tear
protection, focusing on impacts of tear fluid on bacterial virulence factor expression. Results
showed that tear fluid suppressed twitching motility, a type of surface-associated movement
conferred by pili. Previously, we showed that twitching is critical for P. aeruginosa traversal
of corneal epithelia, exit from epithelial cells after internalization, and corneal virulence. Inhi-
bition of twitching by tear fluid was dose-dependent with dilutions to 6.25% retaining activity.
Purified lactoferrin, lysozyme, and contrived tears containing these, and many other, tear
components lacked the activity. Systematic protein fractionation, mass spectrometry, and
immunoprecipitation identified the glycoprotein DMBT1 (Deleted in Malignant Brain Tumors
1) in tear fluid as required. DMBT1 purified from human saliva also inhibited twitching, as
well as P. aeruginosa traversal of human corneal epithelial cells in vitro, and reduced dis-
ease pathology in a murine model of corneal infection. DMBT1 did not affect PilA expres-
sion, nor bacterial intracellular cyclicAMP levels, and suppressed twitching motility of P.
aeruginosa chemotaxis mutants (chpB, pilK), and an adenylate cyclase mutant (cyaB).
However, dot-immunoblot assays showed purified DMBT1 binding of pili extracted from
PAO1 suggesting that twitching inhibition may involve a direct interaction with pili. The latter
could affect extension or retraction of pili, their interactions with biotic or abiotic surfaces, or
cause their aggregation. Together, the data suggest that DMBT1 inhibition of twitching motil-
ity contributes to the mechanisms by which mucosal fluids protect against P. aeruginosa
infection. This study also advances our understanding of how mucosal fluids protect against
infection, and suggests directions for novel biocompatible strategies to protect our surface
epithelia against a major opportunistic pathogen.
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Author summary
Pseudomonas aeruginosa is an opportunistic pathogen that causes life-threatening infec-
tions. P. aeruginosa disease is increasing in prevalence while bacteria continue to evolve
antibiotic resistance. It is not clear how mucosal fluids usually protect against opportunis-
tic pathogens. Knowing the key ingredients would help us understand susceptibility and
develop novel biocompatible therapeutics. Mucosal fluid factors suppressing bacterial vir-
ulence may induce less bacterial resistance than traditional antimicrobials. Here we show
that DMBT1, an abundant mucosal fluid glycoprotein, enabled tear fluid to inhibit P. aer-
uginosa twitching motility. We also show DMBT1 directly binds pili, which mediate
twitching motility, suggesting a potential mechanism for twitching inhibition. Reflecting
the known importance of twitching motility in virulence, purified DMBT1 reduced P. aer-
uginosa traversal of human cornea epithelial cell layers in vitro, and protected against P.
aeruginosa induced disease in vivo, as does whole human tear fluid. These findings con-
tribute to our understanding of mucosal fluid protection against infection, and suggest
that DMBT1, or its derivatives, have potential as novel anti-virulence agents that protect
against infection.
Introduction
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen ubiquitous in our envi-
ronment. It is a leading cause of life-threatening infections in debilitated individuals in the
hospital setting [1], and of sight-threatening corneal disease in healthy people who wear con-
tact lenses [2, 3]. However, the mechanism(s) by which medical devices at any mucosal surface
predispose to infection with P. aeruginosa or other opportunists remains poorly understood
[4, 5].
The surface of the eye is normally bathed in tear fluid, which like other mucosal fluids con-
tains many proteins-peptides, lipids, small molecule metabolites, and electrolytes. Indeed,
more than 1000 proteins have been identified in healthy human tear fluid [6]. In addition to
playing antimicrobial roles, mucosal fluids function to provide lubrication, remove foreign
debris, provide homeostatic factors, and repair epithelial damage [7], Our previous studies
have confirmed that tear fluid collected from healthy people can protect corneas (of mice)
against P. aeruginosa infection in vivo [8].
Of likely relevance to the pathogenesis of contact lens related infections, when a contact
lens is worn it dramatically reduces normal tear exchange between the greater tear fluid reser-
voir and the space between the lens and ocular surface [9, 10]. Suggesting that tear fluid bio-
chemistry is altered under a worn lens, and that this is potentially relevant to the pathogenesis
of infection, bacteria inoculated on the back surface of worn lenses grew more efficiently after
8 h of wear compared to 1 h of wear [11]. Candidate antimicrobial tear components in tear
fluid that could be impacted by lens wear include; complement, defensins, lactoferrin, lipoca-
lin, lysozyme, secretory phospholipase A2, secretory IgA, soluble mucins (Muc5AC), and/or
surfactant proteins (SP-A, SP-D) [12].
However, mechanisms other than antimicrobial activity can also contribute to the protec-
tive activity of tear fluid against P. aeruginosa virulence. Indeed, only ~ 50% of P. aeruginosa
clinical isolates are susceptible to tear fluid bacteriostatic activity [13], but almost all show
reduced virulence in tear fluid. Further, these tear fluid activities are mechanistically separable
[13]. Relevant to this, tear fluid can act directly on epithelial cells to enhance their resistance to
P. aeruginosa virulence [13, 14] through upregulation of epithelial cell innate defense factors,
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e.g. RNase7 and ST2 [14, 15], alterations to microRNA expression [14], and the regulation of
transcription factors NFκB and AP-1 [14]. Non-bacteriostatic activities of tear fluid also
include its capacity to disperse P. aeruginosa biofilms [16], which are thought to be key to the
pathogenesis of device-related infections.
A multitude of P. aeruginosa virulence factors can participate in virulence during corneal
infection, most playing redundant roles but some required for full virulence [4, 17]. Among
the major contributions is twitching motility [18, 19]. Twitching motility is a surface-associ-
ated bacterial movement conferred by extension and retraction of type IV pili (T4P) com-
monly used by Gram-negative bacteria [20]. While assisting bacterial adhesion to surfaces,
retraction of pili can bring bacteria into intimate contact with the surface, allowing it to
migrate away from the initial point of contact or toward an attractant, to reposition cells with
respect to one another (e.g. differentiation within a biofilm), and can also help cells efficiently
escape from surfaces when desirable [21]. In P. aeruginosa, the T4P consist of a polymer of the
PilA major pilin subunit, while the extension and retraction of pili are controlled by ATPases
PilB, PilU and PilT [22, 23]. While twitching motility mutants are able to adhere to, and
invade, human corneal epithelial cells grown in vitro, they have a reduced capacity to exit cells
after invasion [19]. Twitching mutants are also defective in their ability to traverse multilayers
of epithelial cells [19], which may explain their lack of virulence in vivo [18].
Given the protective effect of tear fluid against P. aeruginosa, and the critical role of twitch-
ing in corneal pathogenesis, we examined the impact of tear fluid on twitching motility. Sys-
tematic fractionation of human tear fluid, combined with mass spectrometry and immuno-
precipitation, identified DMBT1 (also known as glycoprotein-340) as required for tear inhibi-
tion of twitching motility. DMBT1 purified from saliva was sufficient when used alone for
inhibiting twitching, preventing P. aeruginosa traversal of multilayered epithelial in vitro, and
for reducing corneal disease severity in a murine model of P. aeruginosa keratitis. These results
suggest a novel function for mucosal fluid and specifically DMBT1 in innate defense against
infection.
Results
Human tear fluid inhibits P. aeruginosa twitching motility
Time-lapse imaging was used to examine the impact of human tear fluid on twitching motility
of P. aeruginosa strain PAO1. For this purpose, specialized agar media was used, absorbed
with undiluted human tear fluid or PBS (see Methods). For each sample, images were collected
with the colony edge positioned half way across the field. To determine speed of bacterial
movement, time-lapse imaging was done by repeated 10 second interval image capture over a
period of 300 seconds. Velocity of the twitching competent P. aeruginosa strain PAO1 was
compared with and without tear fluid added to the media. PAO1-pilA::Tn, lacking twitching
motility, was used as a negative control. Fig 1 shows the edge of representative bacterial colo-
nies over a period of 300 seconds (0, 150 and 300 seconds) for PAO1 with and without tear
fluid, and compared to the pilA twitching mutant control. Comparison of the colony edge at
each time point relative to the dotted white line illustrating the colony edge at the start of the
experiment, showed that tear fluid significantly reduced twitching motility compared to PBS
(Fig 1, S1, S2 and S3 Videos).
Fig 2 shows quantitative analysis of the impact of tear fluid on reducing twitching motility
quantitatively using three methods; i) averaging velocity of all bacteria in the field i.e., bacterial
motility in the whole field was corresponded to the standard deviation (σ) of pixel intensity in
a 5 min movie (Fig 2A and 2B), ii) examining movement of 10 individual bacteria at the colony
edge in a 5 min movie to better represent the concerted movements of twitching [24] (Fig 2C),
DMBT1 inhibition of P. aeruginosa twitching motility and virulence
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and iii) quantifying colony size over time for 3 colonies per sample, based on published data
that surface-associated twitching movement promotes colony expansion on solid surfaces [21]
(Fig 2D). In each instance, tear fluid exposure caused a dose-dependent inhibition of twitching
motility (as measured by reduced bacterial velocity and colony size expansion) after 4 h. Tear
fluid dilutions up to and including as low as 6.25% retained some degree of inhibition (Fig 2C
and 2D). Controls confirmed that tear fluid at 25% dilution, which inhibited twitching motility
similarly to undiluted tears, did not inhibit bacterial growth (Fig 2E).
Since we had previously shown that P. aeruginosa could overcome the cytoprotective activi-
ties of tear fluid with prolonged exposure (8 h or more) [13], we also examined the impact of
tear fluid (25%) on PAO1 twitching motility for up to 24 h. Tear fluid (25%) maintained inhi-
bition of twitching for up to 8 h (Fig 2F and 2G). At 24 h, twitching velocity was very slow in
PBS, and not significantly different from tear fluid-treated PAO1 or the pilA mutant (Fig 2F).
However, tear fluid retained significant inhibition of colony size expansion at 24 h (Fig 2G).
While that result likely reflected the cumulative effects of tear-mediated twitching inhibition, it
suggested that the bacteria do not readily adapt to tear inhibition of twitching, or that the tear
factor(s) involved are not readily compromised.
The above hypotheses were supported by experiments in which P. aeruginosa was pre-
treated with 25% tear fluid on twitching media for 24 h, before transfer to fresh media (PBS or
25% tear fluid) for 4 h. Results showed that 24 h tear pretreatment did not affect bacterial sus-
ceptibility to inhibition of twitching as measured by twitching velocity (Fig 3A) or colony size
expansion (Fig 3B). The data also showed that tear-exposed P. aeruginosa recovered twitching
once placed in PBS indicating reversible inhibition.
Several other P. aeruginosa strains were also tested for susceptibility to tear inhibition of
twitching motility (Fig 4). Strains 6206, PAK, and PA103 were each susceptible to tear inhibi-
tion as measured by reduced velocity (Fig 4A) or reduced colony size expansion (Fig 4B).
Some variability was noted between these strains and PAO1. For example, undiluted tear fluid
Fig 1. Human tear fluid inhibition of P. aeruginosa twitching motility. Captured frames of P. aeruginosa PAO1
twitching motility in a 5 min video after 4 h incubation on twitching media absorbed with PBS or undiluted human tear fluid.
The twitching mutant PAO1-pilA::Tn served as a negative control. A 5 min time-lapse video was captured at 10 s intervals
using a 60 × oil-immersion lens. Dotted lines indicate initial colony edges. Scale bar = 20 μm.
https://doi.org/10.1371/journal.ppat.1006392.g001
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was required for reducing twitching velocity of strains PAK and PA103. Nevertheless, these
data show that tear fluid inhibition of twitching motility is not restricted to one strain.
Identification of DMBT1 as a tear fluid factor inhibiting twitching motility
To begin to identify the tear factor(s) involved in twitching inhibition, human tear fluid was
boiled or treated with proteinase K prior to bacterial exposure. In each instance, tears lost their
Fig 2. Tear fluid inhibition of P. aeruginosa twitching motility in a dose-dependent manner. (A) PAO1 motility was
measured as the standard deviation (σ) of pixel intensity in a 5 min video. Larger standard deviations correspond to greater pixel
intensity modulation resulting from higher bacterial motility. Blue represents slower movement. Scale bar = 50 μm. (B) Effect of
tear fluid concentration on PAO1 twitching motility quantified using the above method. (C) Effect of tear fluid concentration on
PAO1 twitching quantified by displacement of bacteria in the leading edge of the colony from the first to last slide of the same
experiment shown in panel B. Ten single bacteria in the leading edge in each video were tracked. (D) Effect of tear fluid
concentration on PAO1 colony size at time zero and 4 h incubation times on twitching media in the same experiment shown in
panel B. (E) P. aeruginosa PAO1 growth on twitching media in PBS or 25% tear fluid. (F) PAO1 twitching velocity measured in 5
min videos on twitching media with PBS or 25% human tear fluid after different incubation times. (G) PAO1 colony size expansion
on twitching media with PBS or 25% human tear fluid after different incubation times. In each panel, data are expressed as the
mean ± SEM per sample from at least three independent experiments. Significance was determined by one-way ANOVA with
Tukey’s post-hoc analysis for twitching velocity and growth, and two-way ANOVA with Tukey’s post-hoc analysis for colony size.
****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, not significant.
https://doi.org/10.1371/journal.ppat.1006392.g002
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inhibitory effects on twitching motility (Fig 5A and 5B) suggesting a heat-labile protein(s) was
involved. Lysozyme and lactoferrin (alone or combined) at concentrations found in human
tears [25] had no effect on twitching motility (Fig 5C). Commercially available contrived
human tears containing lysozyme, lipocalin, albumin, lactoferrin, and gamma-globulins, and
resembling tear fluid by SDS-PAGE (Fig 5D), also had no effect (Fig 5E). However, separation
of human tear fluid into molecular weight fractions greater or less than ~30 kDa (Fig 5F),
revealed that > ~30 kDa fractions inhibited twitching motility, while < ~30 kDa fractions did
not (P< 0.05, ANOVA) (Fig 5G).
Human tear fluid was separated into 7 fractions by size exclusion chromatography (Fig 6A
& S2A Fig), and each fraction tested for inhibition of twitching motility in duplicate experi-
ments. Consistent with our previous results (Fig 5F), only the high molecular weight fractions
(Fraction 1 in Fig 6A, and Fraction 2 in S2A Fig) significantly inhibited P. aeruginosa PAO1
twitching motility (Fig 6B & S2B Fig). Since the active fraction in the first experiment (S2A &
S2B Fig) was of high molecular weight, a different column material (Superose 6) was used for
Fig 3. P. aeruginosa does not adapt to tear fluid inhibition of twitching motility. PAO1 was pretreated
with PBS or 25% human tear fluid for 24 h on twitching media, then transferred to new twitching media with
PBS or 25% human tear fluid for 4 h. Bacterial twitching velocity in 5 min videos (A) and colony size expansion
(B) were measured. Data are shown as the mean ± SEM per sample from three independent experiments.
Significance was determined using two-way ANOVA with Tukey’s post-hoc analysis. ****, P < 0.0001;
***, P < 0.001; ns, not significant.
https://doi.org/10.1371/journal.ppat.1006392.g003
Fig 4. Human tear fluid inhibition of twitching motility on multiple P. aeruginosa strains. (A) Twitching
velocity of P. aeruginosa strains 6206, PAK, and PA103 under the same experimental conditions used for
PAO1. (B) Colony size on twitching media for P. aeruginosa strains 6206, PAK, and PA103 at 0 and 4 h
incubation times. In each panel, data are expressed as the mean ± SEM per sample from at least three
independent experiments. Significance was determined by one-way ANOVA with Tukey’s post-hoc analysis
for twitching velocity and growth, and two-way ANOVA with Tukey’s post-hoc analysis for colony size.
****, P < 0.0001; ***, P < 0.001; *, P < 0.05; ns, not significant.
https://doi.org/10.1371/journal.ppat.1006392.g004
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the second fractionation to obtain better protein separation. Proteins in the active fractions
(Fraction 1 in Fig 6A, and Fraction 2 in S2A Fig) were analyzed by mass spectrometry. Results
revealed the presence of only 4 proteins; DMBT1 (Deleted in Malignant Brain Tumors 1), ker-
atin 1, keratin 2a and haptoglobin, were present in active fractions of both experiments (Fig
6C & S1 Table).
It has been shown that spectrum counting and mass spectrometry chromatograms correlate
with quantitative changes in protein amount [26]. Considering that large proteins tend to con-
tribute more peptide/spectra than small ones, the NSAF (normalized spectral abundance fac-
tor) was used to account for the effect of protein length on spectral counts, which allowed a
Fig 5. Heat-sensitive protein(s) in human tear fluid > 30 kDa inhibit P. aeruginosa twitching motility. P. aeruginosa PAO1
twitching velocity on twitching media was measured after 4 h. (A) Human tear fluid (25%) heated at 95˚C for 10 min (boiled) then
centrifuged to remove precipitated proteins lost inhibitory activity against twitching. (B) Human tear fluid (25%) treated by proteinase K
(100 μg/mL) at 42˚C for 2 h lost inhibitory activity. (C) Purified lysozyme (2 mg/mL), lactoferrin (2 mg/mL) or a combination cocktail do not
inhibit P. aeruginosa PAO1 twitching motility. (D) Protein analysis of human tears and contrived tears by SDS-PAGE. (E) Contrived tears
do not inhibit P. aeruginosa PAO1 twitching motility. (F) Protein analysis of human tear fluid fractions by SDS-PAGE after separation
using a ~30 kDa cut-off column. (G) Tear fractions > 30 kDa inhibited PAO1 twitching motility. Data are shown as the mean ± SEM per
sample from three independent experiments. Significance was determined using one-way ANOVA with Tukey’s post-hoc analysis.
****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, not significant.
https://doi.org/10.1371/journal.ppat.1006392.g005
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comparison of individual protein abundance in multi-protein complexes [27]. Based on NSAF
values, DMBT1 showed the highest relative abundance in active fractions for both experi-
ments, and was therefore considered the most likely candidate for tear inhibition of P. aerugi-
nosa twitching motility.
To directly evaluate DMBT1 involvement in tear inhibition of twitching motility, DMBT1
was immunoprecipitated from human tear fluid. Human tear fluid-depleted of DMBT1 lost
Fig 6. Identification of DMBT1 as the tear fluid inhibitor of P. aeruginosa twitching motility. (A) Human
tear fluid was separated into 7 fractions using size exclusion chromatography. (B) Effect of tear fractions on
twitching velocity of PAO1 reveals a high Mw fraction retains inhibitory activity. (C) Mass spectrometric
analysis of high Mw tear fractions from two size-exclusion experiments reveal 4 proteins common to fractions
inhibiting twitching motility. (D) DMBT1-depleted human tear fluid does not inhibit twitching motility of PAO1.
(E) Western blot analysis of samples used in (D) shows depletion of DMBT-1 from tear fluid, and partial
depletion by isotype control and protein G only beads control. Data shown in panels B and D as mean ± SEM
from three independent experiments. Significance was determined using a one-way ANOVA with Tukey’s
post-hoc analysis. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, not significant.
https://doi.org/10.1371/journal.ppat.1006392.g006
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inhibition of P. aeruginosa twitching motility compared to 25% tears, with no significant dif-
ference in twitching velocity found between PBS and tear-fluid depleted of DMBT1 (Fig 6D).
It was noted that tear fluid treated with isotype control antibody and protein G only beads par-
tially inhibited twitching motility (Fig 6D). Western immunoblot (Fig 6E) confirmed that
DMBT1 was efficiently removed from tear fluid. Fig 6E also showed that the isotype control
and protein G only beads partially depleted DMBT1 suggesting a degree of non-specific bind-
ing, but consistent with observed partial effects on twitching velocity (Fig 6D). Together, these
data suggested that DMBT1 was required for human tear fluid inhibition of P. aeruginosa
twitching motility.
DMBT1 purified from saliva also inhibits P. aeruginosa twitching motility
DMBT1 is expressed in multiple tissues and body fluids and can undergo modifications that
could affect its function at specific sites [28, 29]. Since DMBT1 is abundant in saliva, we tested
if human saliva could inhibit P. aeruginosa twitching motility. Results confirmed a significant
reduction in P. aeruginosa twitching velocity by human saliva treatment from a mean (± SEM)
of 1.16 (± 0.14) μm/min in PBS controls to 0.27 (± 0.02) μm/min with human saliva treatment
(P< 0.0001, one-way ANOVA, Tukey’s post-hoc analysis). The latter velocity was not signifi-
cantly different from the reduction achieved by 25% tears 0.48 (± 0.06) μm/min (P = 0.2316).
Thus, DMBT1 was purified from human saliva, and tested for inhibition of twitching motility.
DMBT1 purification was achieved by exploiting DMBT1 binding to/aggregation of Streptococ-
cus pyogenes, and the bound DMBT1 then released from the aggregated S. pyogenes with
EDTA treatment [30, 31]. Results (S3 Fig & S2 Table) showed that after purification using S.
pyogenes, DMBT1 was the only protein common in two independent fractions (two experi-
mental replicates), and the major protein in the purified fractions based on NSAF. This frac-
tion was referred to as "purified DMBT1" in subsequent experiments.
The purified DMBT1 fraction from saliva caused a dose-dependent inhibition of PAO1
twitching velocity and colony size expansion (Fig 7A). In each instance, a significant inhibition
was achieved with concentrations of DMBT1 equal to or greater than 12.5 ng/μl (5 μl drop
placed onto twitching media) (Fig 7A). DMBT1 at 1 μg in PBS (placed on twitching media)
also inhibited twitching motility of all of three other P. aeruginosa strains (Fig 7B).
Mass spectrometry analysis of high Mw fractions that inhibit P. aeruginosa twitching motil-
ity, from human tear fluid (S1 Table) or saliva (S2 Table) showed that only DMBT1 was pres-
ent in all samples, and that it was the most abundant protein further supporting the hypothesis
that DMBT1 is responsible for inhibition of twitching motility in tear fluid and saliva.
Saliva-purified DMBT1 inhibits P. aeruginosa traversal of multilayered
human corneal epithelial cells in vitro
Our previous studies have shown that twitching motility contributes to P. aeruginosa traversal
of corneal epithelial cells [19], and that tear fluid protects against P. aeruginosa traversal [8].
Thus, we hypothesized that purified DMBT1 would also inhibit P. aeruginosa traversal of mul-
tilayered human corneal epithelial cells.
Human corneal epithelial cells (hTCEpi) were grown on Transwell filters (3 μm pore-size)
and airlifted for 7 days to form multilayers. P. aeruginosa PAO1 was added to the apical surface
with DMBT1 solution, PBS or human tear fluid. After 3 and 6 h, viable bacteria from the apical
and basal chambers were counted. Human tear fluid (50%) or DMBT1 (100 ng/μl) had no
effect on bacterial growth in the apical chamber (Fig 8A), but significantly inhibited P. aerugi-
nosa traversal at 3 h and 6 h (Fig 8B). As expected, the pilA mutant showed significantly
reduced traversal compared to wild-type PAO1. Transepithelial resistance (TER) was
DMBT1 inhibition of P. aeruginosa twitching motility and virulence
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Fig 7. Saliva-purified DMBT1 inhibits twitching of multiple P. aeruginosa strains. DMBT1 solutions
(5 μl) at different concentrations up to 200 ng/μl DMBT1 in PBS were dropped onto twitching media then
inoculated with bacteria and incubated for 4 h at 37˚C. Twitching velocity and colony size were quantified. (A)
Purified DMBT1 from saliva inhibited P. aeruginosa PAO1 twitching velocity and colony size expansion in a
dose-dependent manner. (B) Purified DMBT1 from saliva (1 μg) inhibited twitching velocity and colony size
expansion in three other P. aeruginosa strains. In each panel, data are expressed as mean ± SEM per sample
from three independent experiments. Significance was determined by one-way ANOVA with Tukey’s post-hoc
analysis for twitching velocity, and two-way ANOVA with Tukey’s post-hoc analysis for colony size.
****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, not significant.
https://doi.org/10.1371/journal.ppat.1006392.g007
Fig 8. DMBT1 purified from saliva inhibits P. aeruginosa traversal of multilayered human corneal epithelial (hTCEpi) cells in
vitro. Traversal of P. aeruginosa PAO1 or its pilA mutant across cultured airlifted human corneal epithelial cells in vitro. PAO1 was
incubated in PBS, treated with 50% human tear fluid, or with 100 ng/μl of DMBT1. The pilA mutant was added in PBS. (A) Viable bacterial
counts (means ± SD) in the apical chamber were determined at 3 and 6 h to evaluate bacterial growth. (B) Viable bacterial counts
(means ± SD) in the basal chamber were determined at 3 and 6 h to estimate traversed bacteria. In each instance significance was
determined using one-way ANOVA with Tukey’s post-hoc analysis. *, P < 0.05. (C) TER (Ωcm2) across the human corneal epithelial
cells over 6 h. A Transwell filter without cells was used as a control. TER values shown represent TER(sample)—TER(bank).
https://doi.org/10.1371/journal.ppat.1006392.g008
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unaffected in each sample over the 6 h incubation (Fig 8C) consistent with our published data
for wild-type P. aeruginosa [19].
DMBT1 purified from saliva protects against P. aeruginosa corneal
infection in vivo
Our previous studies showed that twitching motility was important for P. aeruginosa virulence
in a murine scarification model of corneal infection [18], and that human tear fluid can protect
against P. aeruginosa corneal infection in both scarification and healing injury models [8].
Thus, we explored if DMBT1 could protect against P aeruginosa infection in vivo using a
mouse model.
After scarification injury and 6 h healing, mouse corneas were inoculated with P. aeruginosa
PAO1 in PBS or DMBT1 (see Methods). Representative images (Fig 9A) show that corneas
Fig 9. DMBT1 purified from saliva protects against P. aeruginosa corneal infection. (A) Representative
images of C57BL/6 murine corneas at 24 and 48 h and post-infection with P. aeruginosa PAO1 in PBS or
DMBT1 (150 ng/μL). (B) Schematic for grading disease severity of infected murine corneas. Effect of DMBT1
on corneal infection disease severity scores at 24 and 48 h comparing (C) area of infection, (D) density of
opacity, (E) corneal surface irregularity, and (F) total disease severity, the sum of values shown in (C), (D),
and (E). Data are reported as the mean ± SEM per group over three independent experiments (6 mice per
group in total). Significance of differences between groups was determined using the Mann-Whitney U test.
**, P < 0.01; *, P < 0.05; ns, not significant.
https://doi.org/10.1371/journal.ppat.1006392.g009
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inoculated with PAO1 in PBS presented with clear signs of infection after day 1 that progressed
further by day 2. DMBT1 treated corneas showed reduced disease pathology at day 1, and
greatly reduced pathology at day 2. Quantification of disease severity using a grading system
that accounted for area of infection, density of opacity, and surface irregularity (Fig 9B) [32]
showed DMBT1 treated corneas had a significant reduction in area of infection at day 1 and
day 2 (Fig 9C), and in corneal opacity at day 2 (Fig 9D). Surface irregularity was relatively
unaffected (Fig 9E). Overall disease severity was significantly reduced in DMBT1 treated eye at
both time points (Fig 9F) showing that DMBT1 protected corneas from P. aeruginosa keratitis.
DMBT1 does not affect P. aeruginosa PilA expression or cyclicAMP but
does bind pili
Salivary DMBT1 is a well recognized agglutinin for Gram-positive and Gram-negative bacteria
except P. aeruginosa [31, 33–36]. Tear fluid DMBT1 was also shown to bind Staphylococcus
aureus, but not P. aeruginosa, using anti-DMBT1 antibody in a dot-immunoblot assay [29].
We confirmed that DMBT1 purified from saliva aggregates S. pyogenes [30], but does not
aggregate P. aeruginosa (S4 and S5 Videos), suggesting a novel mechanism for inhibiting P.
aeruginosa twitching motility.
Type IV pilus (T4P) production and twitching motility in P. aeruginosa is controlled by the
Pil-Chp pathway (encoded by gene cluster IV) containing pilG/H/I/J/K and chpA/B/C/D/E
genes [37]. The Chp system controls T4P production by modulation of cyclicAMP; twitching
motility is cyclicAMP-independent [38]. To begin to explore the mechanism for DMBT1 inhi-
bition of twitching motility, we examined some key elements of the pathways involved. West-
ern immunoblots showed no difference in PilA expression by P. aeruginosa PAO1 after
DMBT1 exposure for 4 h (Fig 10A) suggesting that pilin production was unaffected. Purified
DMBT1 also had no effect on cyclicAMP levels in P. aeruginosa PAO1 collected from twitch-
ing media after 4 h (Fig 10B). Since many chemotaxis mutants of P. aeruginosa lose twitching
motility, it is difficult to determine if DMBT1 inhibition of twitching motility involves chemo-
taxis genes [38]. However, the latter study identified three mutants of P. aeruginosa strain PAK
that retained twitching motility; mutants in cyaB (encoding an adenylate cyclase to control
cAMP synthesis), chpB (encoding a methylesterase) which can adjust the methylation status of
the sensor module in the pili-mediated chemotaxis system [37], and pilK (encoding a methyl-
transferase) [38]. In the present study, cyaB, chpB, and pilK mutants of strain PAO1 also
retained twitching motility under control conditions (Fig 10C). DMBT1 inhibited twitching of
all three mutants (Fig 10C), suggesting that those genes are not needed for DMBT1-mediated
twitching inhibition. Dot-immunoblot assays, however, showed that purified DMBT1 could
bind pili extracted from P. aeruginosa strain PAO1 (Fig 10D and 10E), suggesting that the
mechanism for inhibition of twitching motility involves a direct interaction with P. aeruginosa
pili.
Discussion
Previously, we showed that tear fluid could protect human corneal epithelial cells and mouse
corneas against P. aeruginosa infection [8, 19], a protective activity mechanistically separable
from bacteriostatic activity. Here, we explored the mechanisms involved and found that
human tear fluid can inhibit surface-associated twitching motility by P. aeruginosa, dependent
on the glycoprotein DMBT1. DMBT1, also known as GP340, is abundant in various mucosal
fluids. Used alone, DMBT1 purified from saliva inhibited twitching motility, suggesting it is
both necessary and sufficient for the protective activity of tear fluid. DMBT1 did not suppress
P. aeruginosa viability, or aggregate bacteria, and its inhibition of twitching was not associated
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with changes in pilin expression or bacterial cyclicAMP. However, DMBT1 bound pili
extracted from P. aeruginosa suggesting a direct interaction with pili is involved in twitching
inhibition. Reflecting the known importance of twitching in virulence, DMBT1 protected mul-
tilayers of human corneal epithelial cells against P. aeruginosa traversal, and reduced disease
severity in an in vivo animal model. Thus, this glycoprotein, or an active derivative, may have
potential as a biocompatible therapeutic intervention against P. aeruginosa that acts without
suppressing bacterial viability or bacterial aggregation. Although this study was focused on
tear fluid and the cornea, the findings might be broadly applicable to other mucosal surfaces
that P. aeruginosa infects given that DMBT1 is present in human saliva, the small intestine,
and airways [28, 29].
Fig 10. DMBT1 does not affect P. aeruginosa PilA expression or cyclicAMP levels, but inhibits
twitching of PAO1 mutants in cyaB, chpB, and pilK. (A) Western immunoblot of PilA expression in P.
aeruginosa PAO1 after DMBT1 (100 ng/μl) treatment on twitching media for 4 h. PilA protein levels were
unaffected by DMBT1 exposure in all samples (bacteria, vortexed bacteria, and supernatant, see Methods).
(B) CyclicAMP levels of P. aeruginosa PAO1 treated with DMBT1 (100 ng/μl) on twitching media for 4 h. (C)
Effects of DMBT1 (100 ng/μl) on twitching velocity of PAO1 mutants in cyaB, chpB and pilK after 4 h. Data are
shown as the mean ± SEM per sample from three independent experiments. Significance was determined
using one-way ANOVA with Tukey’s post-hoc analysis. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01;
*, P < 0.05; ns, not significant. (D) Dot-immunoblot assay using anti-PilA antibody to show the binding of
PAO1 pili to DMBT1 after 40 min incubation with a pili-containing extract from PAO1. Diluted extracts from
PAO1 (S-PAO1) or its pilA mutant (S-PAO1-pilA::Tn) (see Methods) were used as controls. A representative
experiment of two independent experiments is shown. (E) Quantification of dot-intensity from the dot-
immunoblot assay shown in D. Data are shown as the mean ± SEM of triplicate measurements from each
sample.
https://doi.org/10.1371/journal.ppat.1006392.g010
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DMBT1 was first isolated from saliva using affinity adsorption to Streptococcus mutans, and
identified as a ~300–400 kDa glycoprotein [28]. It belongs to the scavenger receptor cysteine-
rich (SRCR) protein superfamily, which is highly conserved down to sponges as secreted or
membrane-bound proteins [39]. The human chromosome contains one copy of the gene
encoding DMBT1 located on chromosome 10q26.13. However, there are different human
DMBT1 alleles within the population and different isoforms in different tissues governed by
alternative splicing and post-translation modification, e.g. DMBT1 variations include the num-
ber of SRCR domains or patterns of glycosylation [28, 39, 40]. Approximately 25% of the molec-
ular mass of salivary-derived DMBT1SAG (Salivary Agglutinin) is due to glycosylation (~10%
for N-glycosylation, and ~15% for O-glycosylation) [41, 42]. Differences in DMBT1 glycosyla-
tion were reported between saliva-derived DMBT1SAG and lung-derived DMBT1GP340, the lat-
ter lacking Lewis (Le) antigens [43]. Moreover, two isoforms of DMBT1 derived from human
tear fluid expresses sialyl-Lea antigens [44], not sialyl-Lex antigens expressed by DMBT1SAG. In
our studies, DMBT1 depletion from human tear fluid removed inhibition of twitching motility,
while DMBT1 purified from saliva inhibited twitching motility. Thus, reported differences in
sialyl-Le antigens do not affect this function suggesting that tear fluid and salivary DMBT1 iso-
forms share a common domain(s) to fulfill twitching inhibition. Detailed structure function
studies to identify domains inhibiting twitching will require further investigation.
The SRCR domains play a key role in the function of DMBT1 in mucosal immunity as a
bacterial agglutinin that binds many pathogens including Gram-positive and Gram-negative
bacteria, and viruses [31, 33–36]. However, DMBT1 does not aggregate P. aeruginosa strain
PAO1 [29], a finding confirmed in the present study (S4 and S5 Videos).
DMBT1 is known to bind other mucosal fluid antimicrobial and immune defense proteins
including; SP-D [45], SP-A [46], lactoferrin [47] and secretory IgA [48]. Thus, some of its
apparent activities can depend on its binding partners. However, no other known defense fac-
tors were found in the mass spectrometry analysis of the high Mw fractions of tear fluid or
DMBT1 purified from saliva, which both inhibited twitching motility. While the active tear
fraction containing DMBT1 did contain three other proteins in replicate experiments; keratin
1, keratin 2a, and haptoglobin (Fig 4C), none of them were present in the saliva-purified frac-
tions containing DMBT1 that inhibited twitching.
That neither tear fluid nor purified DMBT1 inhibited the growth of P. aeruginosa strain
PAO1 (Figs 2E and 8A) is consistent with our previously published data showing a lack of tear
fluid bacteriostatic activity against many P. aeruginosa isolates [13].
Thus, the mechanism by which DMBT1 inhibits P. aeruginosa twitching motility appears to
be independent of bacterial aggregation, known DMBT1 binding partners, other proteins
present in the active fractions with DMBT1, and bacteriostatic activity. Our data also indicated
that pilin expression, and bacterial cyclicAMP levels were unaffected by DMBT1 exposure,
and DMBT1 could inhibit twitching motility of P. aeruginosa mutants in pilK (encoding a
methyltransferase), chpB (encoding a methylesterase), or cyaB (encoding an adenylate cyclase),
suggesting that none of these factors were involved.
Purified DMBT1 did, however, bind pili extracted from P. aeruginosa PAO1 suggesting that
twitching motility inhibition involves direct interaction with pili. Such interactions could
affect numerous aspects of pilus function including; their extension or retraction, their interac-
tions with surfaces (biotic and abiotic), or cause their aggregation. However, twitching motility
could also be compromised by DMBT1 at other levels including an alteration of gene expres-
sion in the Pil-Chp pathway (or its regulation), or interfering with small molecule regulation,
e.g. cyclic-di-GMP [21, 22]. Targets for future study could include pilus extension or retraction
motor proteins, e.g. ATPases PilB or PilT respectively [49, 50], or the chemosensory protein
PilJ which directly interacts with PilA [23], and also controls pilus extension [51].
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It is possible that DMBT1 interacts with other P. aeruginosa surface antigens or structures,
in addition to pili, that affect twitching motility and/or other bacterial functions. While
DMBT1 did not affect bacterial swimming motility (S5 Video), the full spectrum of DMBT1-P.
aeruginosa interactions, and their consequences, will require further investigation.
The protective mechanism of DMBT1 in our in vitro and in vivo infection models is likely
to involve suppression of twitching motility, given that twitching is critical to pathogenesis in
the cornea [18]. While enabling bacteria to traverse surface epithelial cells, twitching may be
used for trafficking along/through the basal lamina [52], and/or for disseminating within the
underlying corneal stroma [53]. Twitching is also important for biofilm formation [54], a key
virulence determinant when infection is device-related [55, 56].
However, activities of DMBT1 other than inhibition of twitching might have contributed to
its protective activities in our in vivo experiments, for example through binding and associa-
tion with other tear defense proteins. Surfactant protein D (SP-D) which readily binds
DMBT1 can protect corneal epithelial cells against P. aeruginosa invasion [57], and it contrib-
utes to clearing P. aeruginosa from the ocular surface [58]. IgA, another binding partner, can
prevent P. aeruginosa binding to mouse corneas and reduces severity of P. aeruginosa keratitis
[59]. Both factors can also function as opsonins facilitating phagocytosis and clearance of P.
aeruginosa [60, 61]. Also possible, is that DMBT1 influences pathogenesis via direct effects on
resident or infiltrating host cells. Indeed, it can stimulate a dose-dependent chemokinesis (ran-
dom migration) of alveolar macrophages, suggesting role(s) in respiratory inflammatory and
immune responses [46]. It is also able to activate classical and lectin pathways of the comple-
ment system [62, 63]. Teasing apart the relative contributions of different DMBT1 activities in
protecting the cornea against P. aeruginosa infection in vivo will not be straightforward.
Mice also express a homolog of DMBT1 [64]. The ability of P. aeruginosa to infect control
eyes in our study likely reflects characteristics of the infection model, in which murine corneas
were washed with PBS prior to bacterial inoculation, and mice sustained under anesthesia for
4 h after inoculation. This methodology would remove murine tear fluid, and reduce tear flow,
likely compromising the ability of murine DMBT1 to exert protective effects.
In sum, the results of this study suggest that DMBT1 inhibition of twitching motility con-
tributes to mechanisms by which mucosal fluids protect against P. aeruginosa infection, and is
likely accomplished by direct binding to pili. Twitching motility, important to P. aeruginosa
virulence both in vitro and in vivo, is also key to biofilm formation. Thus, discovery that
DMBT1 modulates bacterial virulence factor expression adds to our understanding of how
mucosal fluids defend tissue surfaces against infection. Further, DMBT1 or its derivatives may
hold promise for development of biocompatible strategies for preventing P. aeruginosa infec-
tion that act by altering expression of virulence genes rather than agglutinating bacteria, or
suppressing their viability. Whether wearing a contact lens or other device at mucosal surfaces
impacts the quantity, location, or integrity of DMBT1, and if any changes relate to pathogene-
sis of infection, remains to be determined.
Materials and methods
Ethics statement
Human tear fluid and saliva were collected from healthy volunteers under a protocol approved
by the Committee for the Protection of Human Subjects, University of California Berkeley.
Informed, written consent was obtained from all participants. All procedures involving mice
were carried out in accordance with standards established by the Association for the Research
in Vision and Ophthalmology, under the protocol AUP-2016-08-9021 approved by the
Animal Care and Use Committee, University of California Berkeley, an AAALAC accredited
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institution. The protocol adheres to PHS policy on the humane care and use of laboratory ani-
mals, and the guide for the care and use of laboratory animals. Anesthesia was achieved by
intraperitoneal injection of an anesthetic cocktail containing ketamine (80 mg/Kg) and xyla-
zine (10 mg/Kg), or ketamine (50 mg/Kg) and medetomidine (0.75 mg/Kg) for sustained anes-
thesia. Euthanasia was performed using carbon dioxide inhalation.
Bacterial strains and culture conditions
P. aeruginosa strains PAO1, PAK, PA103 and 6206 were used. Bacteria were grown on tryptic
soy agar (TSA) plates at 37˚C for 16 h to obtain lawn cultures. P. aeruginosa PAO1 transpo-
son insertion mutant pilA::Tn (PW8621) [65] lacking twitching motility, was grown on TSA
with 60 μg/mL tetracycline, and used as a negative control. P. aeruginosa PAO1 transposon
insertion mutants cyaB::Tn (PW6387), chpB::Tn (PW1760) and pilK::Tn (PW1757) [65] were
also grown on TSA with 60 μg/mL tetracycline. Each of the transposon mutants was verified
by PCR (S1 Fig) using previously reported primers [65] or primers designed for pilK. For
twitching motility assays, bacteria were grown on twitching motility Gellan Gum media
(TMGG, 0.8 g Gellan gum, 0.4 g tryptone, 0.2 g yeast extract, 0.2 g NaCl, 0.1 g MgSO47H2O,
in 100 mL H2O) at 37˚C in a humidified chamber for different times. Streptococcus pyogenes
(ATCC19615) was grown in Brain and Heart Infusion (BHI) broth at 37˚C overnight and
used for purification of DMBT1.
Reagents
Tear fluid was collected using a 30 μl volume capillary tube. Subjects were non-contact lens
wearers, males and females, between 18 and 45 years of age, and with no ocular infection or
inflammation at the time of collection. Approximately 5% of the tear fluid from each subject
was plated on TSA to control for bacterial contamination; sterile tear fluid was pooled (from 6
to 8 subjects) and stored at -80˚C until used. In different experiments, human tear fluid (25%)
was boiled at 95˚C for 10 min to denature heat-liable components, treated with proteinase k
(Sigma-Aldrich, 100 μg/mL) at 42˚C for 2 h, or fractionated using sterile water pre-rinsed
Microcon centrifugal filter devices with membrane cutoffs of ~30 kDa (Millipore). Saliva was
obtained from healthy volunteers, clarified by centrifugation at 3,800 x g for 10 min then used
for testing its effect on twitching motility, and for DMBT1 purification as described below.
Purified lactoferrin and lysozyme from human milk (2 mg/mL in PBS) were purchased from
Sigma-Aldrich. Contrived tear fluid containing lysozyme, albumin, and γ-globulins was pur-
chased from Ursa BioScience (MD, USA).
Twitching motility assays
Twitching motility was measured using a method modified from the microscope slide assay
described previously [66]. Bacteria were grown on TSA plates (supplemented with tetracycline
if needed) at 37˚C for 16 h. Twitching motility Gellan Gum media was dried for 20 min in a
sterile airflow (BSL2 Biosafety Cabinet) before use and then 5 μL of tear fluid, PBS or other
solution was dropped onto the twitching media until completely absorbed. Bacteria grown on
TSA were collected, and mixed using a plastic inoculation loop and subsequently inoculated
onto the twitching media using a sterile toothpick to achieve a tip-sized inoculum. A glass cov-
erslip was gently placed onto the twitching media to create an interstitial space. The slides
were then incubated at 37˚C for 4 h unless otherwise stated. After indicated incubation times,
5 min time-lapse videos were captured at 10 s intervals via differential interference contrast
(DIC) microscopy using a Nikon ECLIPS Ti microscope with a 60× oil-immersion objective at
37˚C.
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Quantification of twitching motility
Twitching motility was quantified with three different methods. Firstly, individual bacterial
twitching motility was quantified as the degree to which they modulated light in a DIC image.
To normalize the contrast of each image and eliminate contrast bias in areas of high focus/illu-
mination, a band pass filter (2–40 pixels) was used in ImageJ. The degree of modulation was
measured as the standard deviation of intensity of each pixel during the length of the movie.
The standard deviation map was then thresholded so that only regions containing bacteria
were analyzed. A histogram of the standard deviation map was then used to measure the distri-
bution of bacterial motility in each sample. A notched boxplot was used to represent each
result. In a notched box plot, if the notches do not overlap then the distributions are signifi-
cantly different. Secondly, twitching velocity was measured as the twitching distance of the
colony leading edge divided by time. The bacterial distance traveled in a 5 min video was mea-
sured from location in the first slide to location in the last slide using ImageJ. Different treat-
ment groups for bacteria were done in triplicate and ten bacteria were tracked in each video.
Thirdly, bacterial colony size was measured soon after inoculation onto twitching media (time
zero) and after different incubation times.
Bacterial growth in the presence of tear fluid
P. aeruginosa PAO1 bacteria were grown on TSA media overnight and then diluted to OD600
0.03 by use of TSB (tryptic soy broth) media. One microliter of diluted bacteria was dropped
onto twitching media absorbed with PBS or 25% human tear fluid and incubated at 37˚C for
up to 24 h. After collection and serial dilution in PBS, samples were plated onto TSA agar and
incubated at 37˚C overnight to determine numbers of viable bacteria expressed as Colony
Forming Units (CFU). Experiments were repeated five times.
Size-exclusion chromatography of human tear fluid
Size-exclusion chromatography was performed on an AKTAmicro system using a Superdex
200 10/300 GL column (GE Healthcare) in the first separation, or a Superose 6 10/300 GL col-
umn (GE Healthcare) in the second separation, equilibrated in PBS (pH 7.4). To minimize
peak broadening, short lengths of 0.15 mm i. d. tubing were used between the injection valve
and the fraction collector. Human tear fluid was injected onto the column, and fractions of
250 μl were collected. Protein was detected by UV absorbance at 280 nm. Eluted fractions were
pooled according to protein peaks and concentrated using a ~3 kDa cut-off filter (Millipore).
The activity of eluted fractions against P. aeruginosa twitching motility was then assessed as
described above.
Mass spectrometry
Mass spectrometry (MS) was performed at the Proteomics/Mass Spectrometry Laboratory,
University of California, Berkeley. A nano LC column was packed in a 100 μm inner diameter
glass capillary with an emitter tip. The column consisted of 10 cm of Polaris C18 5 μm packing
material (Varian, Agilent, CA), followed by 4 cm of Partisphere 5 SCX (Whatman, Sigma-
Aldrich, MO). The column was loaded by use of a pressure bomb and washed extensively with
buffer A (see below). The column was then directly coupled to an electrospray ionization
source mounted on a Thermo-Fisher LTQ XL linear ion trap mass spectrometer. An Agilent
1200 HPLC equipped with a split line to deliver a flow rate of 300 nl/min was used for chroma-
tography. Peptides were eluted using a 4-step MudPIT procedure [67]. Buffer A was 5% aceto-
nitrile/ 0.02% heptaflurobutyric acid (HFBA); buffer B was 80% acetonitrile/ 0.02% HFBA.
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Buffer C was 250 mM ammonium acetate/ 5% acetonitrile/ 0.02% HFBA; buffer D was same as
buffer C, but with 500 mM ammonium acetate.
Protein identification and quantification were done with Integrated Proteomics Pipeline
(IP2, Integrated Proteomics Applications, Inc. San Diego, CA) using ProLuCID/Sequest,
DTASelect2 and Census [68–70]. Tandem mass spectra were extracted into ms1 and ms2 files
from raw files using RawExtractor [71], and searched against the human protein database plus
sequences of common contaminants, concatenated to a decoy database in which the sequence
for each entry in the original database was reversed [72].
Immunoprecipitation of DMBT1
Immunoprecipitation was performed using mouse monoclonal anti-DMBT1 antibody
(ab17779, Abcam, MA), or a mouse IgG1 isotype control (Thermo Fisher, NY), and protein
G-magnetic beads (New England BioLabs, MA) according to manufacturer’s protocols. After
coating protein G magnetic beads with either DMBT1 antibody or isotype control in a 20 μl
reaction, the complex was incubated with 25 μl of 25% tears for 60 min at 4˚C. Non-coated
protein G magnetic beads were also used as a negative control. The supernatant was then col-
lected for assessing its activity on twitching motility, and its DMBT1 protein content by West-
ern immunoblotting (anti-DMBT1 antibody was diluted 1:1000). The beads were washed 3
times with PBS and then eluted with 20 μl of 0.1 M glycine (pH 2.5) for 3 min at room temper-
ature twice. The supernatant was collected and neutralized with 2 M tris (pH 9.0). The proteins
bound to beads were analyzed by MS as described previously.
Purification of DMBT1 from human saliva
DMBT1 was purified from human saliva rather than tear fluid because saliva is more abundant
and easier to collect. Purification of DMBT1 was performed as described previously [31, 73].
Briefly, clarified saliva was diluted 50% with PBS. Streptococcus pyogenes was incubated in BHI
broth overnight at 37˚C, collected by centrifugation at 3,800 x g for 5 min, and washed three
times with PBS. Bacterial concentration was adjusted to ~5 x109 CFU/mL. Equal volumes of
bacterial suspension and diluted saliva were then mixed and incubated at 37˚C for 60 min.
Bacterial cells were collected again by centrifugation at 3,800 x g for 5 min, and washed three
times with PBS. PBS (1.5 mL) containing 5 mM EDTA was then used to release bound protein
at room temperature for 5 min. The bacterial culture was centrifuged at 15,000 x g for 5 min,
the supernatant filtered using a 0.22 μm filter, and then dialyzed (Slide-A-Lyzer dialysis cas-
settes, Thermo Fisher, NY) against PBS at 4˚C overnight. Dialyzed eluate was subjected to gel
filtration chromatography on a Superose 6 10/300 GL column (GE Healthcare, CA) equili-
brated in PBS (pH 7.4). The eluate at void volume was collected and used as purified DMBT1
from saliva. The presence and purity of DMBT1 was verified by mass spectrometry as
described above. DMBT1 concentration was measured using a micro BCA protein assay kit
(Thermo Scientific, IL, USA).
Bacterial traversal assay
Telomerase-immortalized human corneal epithelial cells (~ 6 × 104 cells) were seeded onto
24-well polyester tissue culture treated Transwell™ inserts (3 μm pore size, Corning Costar,
NY) in KGM-2 medium containing 1.15 mM CaCl2 for 7 days, then airlifted for 7 days as pre-
viously described [74]. P. aeruginosa strain PAO1, or its pilA mutant (~1.3 × 106 CFU) was
inoculated on the apical surface of the cells in PBS, human tear fluid (50% in PBS) or DMBT1
(100 ng/μl in PBS) for 6 h at 37˚C (5% CO2). Transepithelial resistance (TER) (Ocm2) was
measured using an Epithelial Voltohmeter (World Precision Instruments, Inc., FL) before
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inoculating the bacteria, and after 6 h incubation. Transwell™ inserts without corneal cells
served as negative controls. After 3 and 6 h, bacterial viable counts in the apical and basal
chambers were determined to measure bacterial growth and epithelial traversal.
Murine corneal infection
All procedures were approved by the University of California, Berkeley Animal Care and Use
Committee. The scarification with healing murine model of corneal infection was used as pre-
viously described [8] with minor modification. Briefly, C57BL/6 mice (6 to 12 weeks old) were
anesthetized by intraperitoneal injection of an anesthetic cocktail containing ketamine (80
mg/Kg) and xylazine (10 mg/Kg). Eyes were checked for corneal clarity using a stereomicro-
scope prior to the initiation of experiments. Three parallel scratches were made on the right
cornea of each anesthetized animal using a sterile 25 5/8-gauge needle. Mice were checked
every 15 min until they woke up. After 6 h of epithelial healing, mice were anesthetized with a
cocktail containing ketamine (50 mg/Kg) and medetomidine (0.75 mg/Kg), 70 μl per 25 g of
body weight. Healing corneas were then washed with PBS (500 μl), then inoculated with 5 μl of
a P. aeruginosa PAO1 suspension containing ~2 ×103 CFU bacteria in DMEM mixed with
either PBS or 200 ng/μl of DMBT1 at a ratio of 1:3. After 4 h infection under sustained anesthe-
sia, an anesthesia reversal agent, atipamezole (3.75 mg/Kg), 50 μl per 25 g of body weight, was
used to wake the mice. Mice were observed daily and ocular images were captured at 24 and
48 h post-inoculation using 2–3% isoflurane in oxygen inhalation for anesthesia. Corneal dis-
ease severity was graded by a masked observer using a previously described scoring system
[32], which assesses area of infection, density of opacity, surface regularity and overall disease
severity.
Immunoblot assays
To study the effects of DMBT1 on pilin expression, PilA was measured by Western immu-
noblot using sample preparation methods based on previous studies [75]. PAO1 or its pilA
mutant were treated with PBS or DMBT1 (100 ng/μl) as described above in the twitching
motility assays section. After 4 h incubation, bacteria were washed from the twitching
media and cover-slip with 50 mM Na2CO3 (pH 9.6). Bacterial OD600 was adjusted to 0.6,
and 300 μl of bacterial culture centrifuged at 13,000 x g for 5 min, and re-suspended into
SDS-PAGE sample buffer ("bacteria" sample). Another 300 μl of bacterial culture was exten-
sively vortexed for 3 min to remove pili, centrifuged at 15,000 x g for 20 min, and the pellet
dissolved in SDS-PAGE sample buffer ("vortexed bacteria" sample). The supernatant was
placed at 4˚C overnight, after adding MgCl2 to a concentration of 100 mM, and the next day
centrifuged at 15,000 x g for 20 min. The pellet was dissolved in same volume of SDS-PAGE
sample buffer ("supernatant" sample). All samples were heated at 95˚C for 10 min, separated
by SDS-PAGE (20% gel), and probed with antibody to PilA (1:5000) (a kind gift from Dr.
Joanne Engel, University of California, San Francisco), then goat anti rabbit-HRP antibody
(1:5000, Abcam, MA).
Dot-immunoblotting was used to test if DMBT1 could bind P. aeruginosa pili. Briefly, to
prepare an extract of pili, a suspension of P. aeruginosa PAO1 in PBS was prepared to an
OD600 of ~10. The suspension was vortexed for 3 min, centrifuged at 15,000 x g for 20 min,
and the supernatant collected. MgCl2 solution (1 M) was added to the supernatant to a final
concentration of 100 mM, and the supernatant placed at 4˚C overnight. After centrifugation at
15,000 x g for 20 min, the pellet was resuspended in PBS (500 μl) to form a pili-containing
extract. The same method was used to prepare a negative control extract of PAO1-pilA::Tn.
For dot-immunoblot assays, 2 μl of DMBT1 in PBS (400 ng/μl and serial dilutions in PBS)
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were spotted onto a nitrocellulose membrane (0.2 μm pore-size, BioRad), along with a PBS
control, the pili-containing extract from PAO1 (positive control), and the extract from the
pilA mutant (negative control). The extracts were diluted 1 in 500 in PBS for use as controls.
After the membrane was dry, it was blocked with 5% BSA for 1 h at room temperature, then
washed with PBS for 5 min. The membrane was then incubated with the original (undiluted)
pili-containing extract of PAO1 for 40 min at room temperature, then washed 5 times with
PBS. Membranes were then probed with anti-PilA primary antibody (1:5000) and Goat anti-
Rabbit HRP-conjugated secondary antibody (1:5000). Dot intensity was measured using
AlphaView FluoChem HD2 software.
CyclicAMP assay
Intracellular cyclicAMP of P. aeruginosa was measured as described previously [38] with
minor modification. PAO1 was incubated on twitching media with DMBT1 (100 ng/μl) or
PBS at 37˚C for 4 h as described above in twitching motility assays. Bacteria were washed from
twitching media with 0.9 M NaCl at 4˚C, made with superpure water from Cayman Chemical
(Ann Arbor, MI) and kept on ice. Bacterial suspensions were adjusted to the same OD600 value
of ~1.0. Two equal volumes of each suspension were centrifuged at 13,000 x g for 2 min at 4˚C,
and the bacterial pellets washed twice with 1 mL of cold 0.9 M NaCl (final OD600 ~ 2.5). Bacte-
rial pellets were suspended in 200 μl of 0.1 N HCl (made with superpure water) and incubated
on ice for 10 min with occasional vortexing to lyse the bacteria. Lysates were centrifuged at
13,000 x g for 5 min at 4˚C to remove cellular material, and the supernatant was assayed for
cAMP concentration using a Cyclic AMP EIA Kit (Cayman Chemical) following the manufac-
turer’s protocol for sample acetylation.
Statistical analysis
Data were expressed as a mean ± standard error of mean (SEM) unless otherwise stated. The
significance of differences between groups was assessed by one or two-way ANOVA with
Tukey’s post-hoc analysis, or using the Mann-Whitney U test for in vivo experiments. P values
of less than 0.05 were considered significant.
Supporting information
S1 Video. P. aeruginosaPAO1 twitching motility in PBS. Represents a 5 min time-lapse
movie of P. aeruginosa twitching motility captured at an interval of 10 s with a 60 × oil-immer-
sion lens. Scale bar = 20 μm. Frame rate = 10 fps.
(AVI)
S2 Video. Human tear fluid inhibition of PAO1 twitching motility. Represents a 5 min
time-lapse movie of P. aeruginosa twitching motility captured at an interval of 10 s with a
60 × oil-immersion lens. Scale bar = 20 μm. Frame rate = 10 fps.
(AVI)
S3 Video. A twitching motility negative pilA mutant PAO1-pilA::Tn. Represents a 5 min
time-lapse movie of P. aeruginosa twitching motility captured at an interval of 10 s with a
60 × oil-immersion lens. Scale bar = 20 μm. Frame rate = 10 fps.
(AVI)
S4 Video. P. aeruginosaPAO1 movement in PBS at 37˚C for 4 h. Represents a 10 s time-lapse
movie of P. aeruginosa movement captured at no delay with a 40 × lens. Frame rate = 10 fps.
(AVI)
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S5 Video. PAO1 movement in purified DMBT1 (100 ng/μl) at 37˚C for 4 h. Represents a 10
s time-lapse movie of P. aeruginosa movement captured at no delay with a 40 × lens. Frame
rate = 10 fps.
(AVI)
S1 Fig. PCR verification of P. aeruginosaPAO1 transposon insertion mutants. PAO1-
pilA::Tn (PW8621), PAO1-cyaB::Tn (PW6387), and PAO1-chpB::Tn (PW1760) were verified
by PCR with primers provided by the insertion mutant library database. PAO1-pilK::Tn
(PW1757) was verified by PCR with the following primers; pilK flanking primers pilK-F
(5’-AGATGCGCAACTCGGTATCC-3’) and pilK-R (5’-TTCAGGGTTTCGGCGATCTC-3’).
The red square was used to label target products.
(TIF)
S2 Fig. (A) Fractions of human tear fluid separated by size exclusion chromatography (first
experiment). (B) Effect of tear fractions on P. aeruginosa PAO1 twitching velocity measured in
5 min videos of each sample. Data are expressed as the mean ± SEM per sample from three
independent experiments. Significance was determined using one-way ANOVA with Tukey’s
post-hoc analysis.  P < 0.0001, P< 0.001.
(TIF)
S3 Fig. DMBT1 purification from human saliva. (A) SDS-PAGE with silver stain (left panel)
suggested DMBT1 was present after S. pyogenes treatment, and was confirmed by Western
immunoblot (right panel) using anti-DMBT1 antibody. (B) and (C) Two independent experi-
ments each showing that size-exclusion chromatography after DMBT1 purification from
human saliva using S. pyogenes generated a high Mw fraction (fraction 1). Proteins were
separated from aggregated S. pyogenes in human saliva using EDTA (5 mM). (D) Mass spec-
trometric analysis of fraction 1 after DMBT1 purification from saliva revealed the presence of
DMBT1 in two independent experiments.
(TIF)
S1 Table. Mass spectrometry results of human tear fluid fractions that inhibited twitching
motility of P. aeruginosaPAO1. Results shown for two independent fractionations of human
tear fluid using size-exclusion chromatography.
(TIF)
S2 Table. Mass spectrometry results of two independent fractions obtained by size-exclu-
sion chromatography after DMBT1 purification from saliva using S. pyogenes. Each frac-
tion inhibited twitching motility of P. aeruginosa PAO1. Results represent two independent
experiments.
(TIF)
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